Bli medlem
Bli medlem

Du är här

2016-11-21

Novartis International AG: Novartis acquires Selexys Pharmaceuticals Corporation and SelG1 antibody for reduction of pain crises in sickle cell disease (SCD)

Novartis International AG / Novartis acquires Selexys Pharmaceuticals
Corporation and SelG1 antibody forreduction of pain crises in sickle cell
disease (SCD) . Processed and transmitted by Nasdaq Corporate Solutions.The
issuer is solely responsible for the content of this announcement.
* Deal followed results of Phase II SUSTAIN study of SelG1 in reduction of
vaso-occlusive pain crises, a major complication of SCD with limited
treatment options
* Results of SUSTAIN will be presented in the Plenary Scientific Session at
the 58th American Society of Hematology (ASH) Annual Meeting
* Acquisition complements and broadens Novartis' hematology pipeline and
underscores commitment to improving care for patients with high unmet need

Basel, November 21, 2016
-
Novartis today announced it has acquired Selexys Pharmaceuticals Corporation,
a company specializing in development of therapeutics in certain hematologic
and inflammatory disorders. Novartis exercised its right to acquire Selexys
following receipt of results of the SUSTAIN study, a Phase II trial
evaluating the use of SelG1, an anti-P-selectin antibody, in the reduction of
vaso-occlusive pain crises in patients with sickle cell disease (SCD).
Results from the study will be presented during the Plenary Scientific
Session at the 58thAmerican Society of Hematology (ASH) Annual Meeting on
December 4, 2016, in San Diego, California.

"Sickle cell disease affects millions of people around the world and there are
limited therapies available for treatment of vaso-occlusive pain crises, a
very common complication of the disease," said Bruno Strigini, CEO of
Novartis Oncology. "With this acquisition, Novartis is able to leverage its
leadership in hematology research to advance development of a potential new
treatment option for patients living with this debilitating condition."

SCD is a hereditary blood disorder characterized by sickle-shaped red blood
cells[1]. It is a life-long disease with many forms that can range in
clinical severity from asymptomatic to life-threatening.[1]Vaso-occlusive
crises, or pain crises, are the major reason for health care encounters in
SCD and occur episodically when sickle-shaped red blood cells block blood
flow through blood vessels.[2],[3]

"We would like to extend our gratitude to all of the dedicated patients,
physicians and nurses who participated in the SUSTAIN study of SelG1 in
sickle cell disease," said Dr. Scott Rollins, former President and Chief
Executive Officer of Selexys Pharmaceuticals. "Further, the acquisition of
Selexys by Novartis represents an important step in the continued development
of SelG1, a novel, potential first-in-class therapy for patients with this
underserved life-threatening disease."

Novartis obtained the exclusive right to acquire Selexys and SelG1 in 2012.
Prior to the acquisition, Selexys Pharmaceutical Corporation was a privately
held biopharmaceutical company headquartered in Oklahoma City, Oklahoma.
Terms of the deal could total up to $665 million in upfront, acquisition and
milestone payments.

Disclaimer

The foregoing release contains forward-looking statements that can be
identified by words such as "will," "pipeline," "commitment," "potential,"
"important step," "continued development," or similar terms, or by express or
implied discussions regarding potential benefits, synergies or opportunities
as a result of the acquisition of Selexys Pharmaceuticals Corporation and
SelG1, potential marketing approvals for SelG1 and the other product
candidates in the Novartis hematology pipeline, or regarding potential future
revenues from SelG1 and such other product candidates. You should not place
undue reliance on these statements. Such forward-looking statements are based
on the current beliefs and expectations of management regarding future
events, and are subject to significant known and unknown risks and
uncertainties. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual results
may vary materially from those set forth in the forward-looking statements.
There can be no guarantee that Novartis will be able to realize any or all of
the potential benefits, synergies or opportunities as a result of the
acquisition of Selexys Pharmaceuticals Corporation and SelG1. Neither can
there be any guarantee that SelG1 or the other product candidates in the
Novartis hematology pipeline will be submitted or approved for sale in any
market, or at any particular time. Nor can there be any guarantee that SelG1
or the other product candidates in the Novartis hematology pipeline will be
commercially successful in the future. In particular, management's
expectations regarding the acquisition of Selexys Pharmaceuticals Corporation
and SelG1, and the other product candidates in the Novartis hematology
portfolio could be affected by, among other things, the possibility that the
potential benefits, synergies or opportunities expected from the acquisition
may not be realized or may take longer to realize than expected; the
uncertainties inherent in research and development, including unexpected
clinical trial results and additional analysis of existing clinical data;
unexpected regulatory actions or delays or government regulation generally;
the company's ability to obtain or maintain proprietary intellectual property
protection; general economic and industry conditions; global trends toward
health care cost containment, including ongoing pricing pressures; unexpected
safety, quality or manufacturing issues, and other risks and factors referred
to in Novartis AG's current Form 20-F on file with the US Securities and
Exchange Commission. Novartis is providing the information in this press
release as of this date and does not undertake any obligation to update any
forward-looking statements contained in this press release as a result of new
information, future events or otherwise.

About Novartis

Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland,
Novartis offers a diversified portfolio to best meet these needs: innovative
medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the
only global company with leading positions in these areas. In 2015, the Group
achieved net sales of USD 49.4 billion, while R&D throughout the Group
amounted to approximately USD 8.9 billion (USD 8.7 billion excluding
impairment and amortization charges). Novartis Group companies employ
approximately 118,000 full-time-equivalent associates. Novartis products are
available in more than 180 countries around the world. For more information,
please visithttp://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis
athttp://twitter.com/novartisand @NovartisCancer
athttp://twitter.com/novartiscancer

For Novartis multimedia content, please
visitwww.novartis.com/news/media-library

For questions about the site or required registration, please
contactmedia.relations@novartis.com

References

[1] National Heart, Lunch and Blood Institute. What Is Sickle Cell Disease?
Last updated: August 2, 2016. Available
from:http://www.nhlbi.nih.gov/health/health-topics/topics/sca. Accessed on
October 13, 2016.

[2] Solomon LR. Treatment and prevention of pain due to vaso-occlusive crises
in adults with sickle cell disease: an educational void.Blood
. 2008;111(3):997-1003. Published online October 16, 2007. Available
from:http://www.ncbi.nlm.nih.gov/pubmed/17940207. Accessed October 13, 2016.

[3] The Mayo Clinic. Diseases and Conditions: Sickle Cell Anemia. Mayo Clinic
Staff. Last updated June 2014. Available
fromhttp://www.mayoclinic.org/diseases-conditions/sickle-cell-anemia/basics/....
Accessed October 13, 2016.

# # #

Novartis Media Relations

Central media line: +41 61 324 2200
E-mail:media.relations@novartis.com

-------------------------------------------------------------------
| Eric Althoff Jeannie Neufeld |
|Novartis Global Media Relations |
|+41 61 324 7999 (direct) Novartis Oncology Communications |
|+41 79 593 4202 (mobile) +1 862 778 2104 (direct) |
|eric.althoff@novartis.com +1 201 650 2728 (mobile) |
| jeannie.neufeld@novartis.com |
-------------------------------------------------------------------
Novartis Investor Relations

Central investor relations line: +41 61 324 7944
E-mail:investor.relations@novartis.com

------------------------------------------------------------------------
| Central North America |
| Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448 |
| Pierre-Michel Bringer +41 61 324 1065 Sloan Pavsner +1 212 830 2417 |
| Thomas Hungerbuehler +41 61 324 8425 |
| Isabella Zinck +41 61 324 7188 |
------------------------------------------------------------------------

Media release (PDF)
http://hugin.info/134323/R/2058142/771288.pdf

---------------------------------------
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novartis International AG via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.